Corentec코렌텍

Corentec's trailing profits have recovered to about ₩7.7B net income, with the share price up 27% over three months but still down 2% over a year.

Corentec is a Korean maker of orthopedic joint implants, mainly artificial hips and knees, with a subsidiary providing health checkups and a US ambulatory surgery center. On trailing twelve months to H1 2026 it reported revenue of ₩104.8B, operating income of ₩9.0B and net income of ₩7.7B, with ₩23.1B cash against ₩28.9B borrowings. The shares closed at ₩4,960, well below the 52-week high of ₩7,440, and the data shows no dividend.

What stands out

• Trailing revenue of ₩104.8B and operating margin of 8.6% are close to 2025's full-year levels of ₩100.4B and 9.1%.
• The 2024 year was weak, with a net loss of ₩1.3B on revenue of ₩93.7B, so earnings history is uneven.
• Trailing net income of ₩7.7B gives a P/E of 8.7 and P/B of 0.8, below the peers listed in the data, which range from P/E 12.4 to 66.3.
• The base-case DCF value in the data is ₩8,022 per share, above the current price, but the bear case is ₩3,501 and the bull case ₩16,159, a wide range that depends on the model's assumptions.
• Foreign ownership rose from 3.5% to 3.9% over 60 days, while institutions were net sellers over the last 20 days.

What to watch

• The Q3 2026 quarterly report and any updated preliminary earnings, to check whether margins hold near 8.6%.
• Liabilities at 75.5% of equity and borrowings of ₩28.9B against cash of ₩23.1B, which the filings will show over coming periods.
• The data includes no news headlines and no analyst coverage, so there is no outside commentary on the recent share price rise.